Leukaemia cell of origin identified by chromatin landscape of bulk tumour cells.
Joshy GeorgeAsli UyarKira YoungLauren KufflerKaiden Waldron-FrancisEladio J MárquezDuygu UcarJennifer J TrowbridgePublished in: Nature communications (2016)
The precise identity of a tumour's cell of origin can influence disease prognosis and outcome. Methods to reliably define tumour cell of origin from primary, bulk tumour cell samples has been a challenge. Here we use a well-defined model of MLL-rearranged acute myeloid leukaemia (AML) to demonstrate that transforming haematopoietic stem cells (HSCs) and multipotent progenitors results in more aggressive AML than transforming committed progenitor cells. Transcriptome profiling reveals a gene expression signature broadly distinguishing stem cell-derived versus progenitor cell-derived AML, including genes involved in immune escape, extravasation and small GTPase signal transduction. However, whole-genome profiling of open chromatin reveals precise and robust biomarkers reflecting each cell of origin tested, from bulk AML tumour cell sampling. We find that bulk AML tumour cells exhibit distinct open chromatin loci that reflect the transformed cell of origin and suggest that open chromatin patterns may be leveraged as prognostic signatures in human AML.
Keyphrases
- single cell
- gene expression
- acute myeloid leukemia
- cell therapy
- stem cells
- genome wide
- rna seq
- transcription factor
- endothelial cells
- dna methylation
- bone marrow
- acute lymphoblastic leukemia
- mesenchymal stem cells
- intensive care unit
- cell proliferation
- hepatitis b virus
- drug induced
- respiratory failure
- acute respiratory distress syndrome
- protein protein